Richard B Rothman

List of Publications by Year
in descending order

361 papers	17,883 citations	14655 66 h-index	21540 114 g-index
377 all docs	377 docs citations	377 times ranked	8896 citing authors

#	Article	IF	Citations
1	Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 2001, 39, 32-41.	1.2	825
2	Salvinorin A: A potent naturally occurring nonnitrogenous Â opioid selective agonist. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11934-11939.	7.1	712
3	Evidence for Possible Involvement of 5-HT _{2B} Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications. Circulation, 2000, 102, 2836-2841.	1.6	659
4	Monoamine transporters and psychostimulant drugs. European Journal of Pharmacology, 2003, 479, 23-40.	3.5	414
5	The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue. Neuropsychopharmacology, 2012, 37, 1192-1203.	5.4	386
6	Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive â€˜Bath Saltsâ€™ Products. Neuropsychopharmacology, 2013, 38, 552-562.	5.4	361
7	Depressive-Like Effects of the Î²-Opioid Receptor Agonist Salvinorin A on Behavior and Neurochemistry in Rats. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 440-447.	2.5	340
8	N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity. Neuropsychopharmacology, 2008, 33, 2303-2312.	5.4	282
9	3,4-Methylenedioxymethamphetamine (MDMA, â€œEcstasyâ€) Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro. Molecular Pharmacology, 2003, 63, 1223-1229.	2.3	263
10	Mu and delta receptors: Their role in analgesia and in the differential effects of opioid peptides on analgesia. Life Sciences, 1982, 30, 1443-1455.	4.3	223
11	3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology, 2007, 189, 407-424.	3.1	214
12	N-Substituted Piperazines Abused by Humans Mimic the Molecular Mechanism of 3,4-Methylenedioxymethamphetamine (MDMA, or â€˜Ecstasyâ€™). Neuropsychopharmacology, 2005, 30, 550-560.	5.4	211
13	Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of (+)-4-[(.alpha.R)-.alpha.-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A Highly Selective, Nonpeptide .delta. Opioid Receptor Agonist. Journal of Medicinal Chemistry, 1994, 37, 2125-2128.	6.4	210
14	Aminorex, Fenfluramine, and Chlorphentermine Are Serotonin Transporter Substrates. Circulation, 1999, 100, 869-875.	1.6	201
15	Autoradiographic localization of Î¼- and Î´-opiate receptors in the forebrain of the rat. Brain Research, 1986, 378, 49-60.	2.2	172
16	Distribution of opiate receptor subtypes and enkephalin and dynorphin immunoreactivity in the hippocampus of squirrel, guinea pig, rat, and hamster. Journal of Comparative Neurology, 1987, 255, 497-510.	1.6	169
17	Evidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 738-746.	2.5	169
18	Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology, 1992, 103, 630-635.	1.3	167

#	Article	IF	Citations
19	In Vitro Characterization of Ephedrine-Related Stereoisomers at Biogenic Amine Transporters and the Receptorome Reveals Selective Actions as Norepinephrine Transporter Substrates. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 138-145.	2.5	167
20	A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse, 1992, 12, 129-138.	1.2	156
21	Therapeutic and adverse actions of serotonin transporter substrates. , 2002, 95, 73-88.		156
22	A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Molecular Neurobiology, 1995, 11, 1-19.	4.0	153
23	Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides, 1990, 11, 311-331.	2.4	141
24	Central mu-opioid receptors are down-regulated in a rat model of cholestasis. Journal of Hepatology, 1992, 15, 220-224.	3.7	139
25	Neoclerodane Diterpenes as a Novel Scaffold for Î¼ Opioid Receptor Ligandsâ€. Journal of Medicinal Chemistry, 2005, 48, 4765-4771.	6.4	139
26	Opiate receptors in rat pituitary are confined to the neural lobe and are exclusively kappa. Brain Research, 1986, 382, 365-371.	2.2	132
27	Serotonergic drugs and valvular heart disease. Expert Opinion on Drug Safety, 2009, 8, 317-329.	2.4	128
28	Serotonin releasing agents. Pharmacology Biochemistry and Behavior, 2002, 71, 825-836.	2.9	124
29	Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 237-246.	2.5	119
30	High affinity dopamine reuptake inhibitors as potential cocaine antagonists: A strategy for drug development. Life Sciences, 1990, 46, PL17-PL21.	4.3	118
31	Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug and Alcohol Dependence, 2015, 147, 1-19.	3.2	116
32	GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacology Biochemistry and Behavior, 1991, 40, 387-397.	2.9	113
33	Identification of the Firsttrans-(3R,4R)- Dimethyl-4-(3-hydroxyphenyl)piperidine Derivative To Possess Highly Potent and Selective Opioid Î¹ Receptor Antagonist Activity. Journal of Medicinal Chemistry, 2001, 44, 2687-2690.	6.4	110
34	Balance between Dopamine and Serotonin Release Modulates Behavioral Effects of Amphetamine-Type Drugs. Annals of the New York Academy of Sciences, 2006, 1074, 245-260.	3.8	108
35	Neuropharmacology of the Naturally Occurring Î¹-Opioid Hallucinogen Salvinorin A. Pharmacological Reviews, 2011, 63, 316-347.	16.0	106
36	Visualization of rat brain receptors for the neuropeptide, substance P. Brain Research, 1984, 309, 47-54.	2.2	104

#	Article	IF	Citations
37	Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacology Biochemistry and Behavior, 2008, 90, 208-217.	2.9	97
38	Nonclassical Pharmacology of the Dopamine Transporter: Atypical Inhibitors, Allosteric Modulators, and Partial Substrates. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 2-10.	2.5	97
39	A comparative autoradiographic study of the distributions of substance P and eledoisin binding sites in rat brain. Brain Research, 1986, 385, 273-281.	2.2	96
40	In Vivo Effects of Amphetamine Analogs Reveal Evidence for Serotonergic Inhibition of Mesolimbic Dopamine Transmission in the Rat. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 218-225.	2.5	95
41	Chronic morphine increases Î¼-opiate receptor binding in rat brain: a quantitative autoradiographic study. Brain Research, 1989, 477, 382-386.	2.2	94
42	Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sciences, 1995, 57, PL45-PL50.	4.3	93
43	Salvinorin A Analogs as Probes in Opioid Pharmacology. Chemical Reviews, 2008, 108, 1732-1743.	47.7	90
44	Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Molecular Brain Research, 1999, 73, 37-49.	2.3	89
45	Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers. Biological Psychiatry, 1995, 38, 751-755.	1.3	88
46	How Physician Obesity Specialists Use Drugs to Treat Obesity. Obesity, 2009, 17, 1730-1735.	3.0	88
47	Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans. Biological Psychiatry, 1998, 44, 578-591.	1.3	87
48	Î²2Opioid Receptors in Limbic Areas of the Human Brain Are Upregulated by Cocaine in Fatal Overdose Victims. Journal of Neuroscience, 1997, 17, 8225-8233.	3.6	86
49	Morphine tolerance increases Î¼-noncompetative Î´ binding sites. European Journal of Pharmacology, 1986, 124, 113-119.	3.5	84
50	Modulation of Î¼-mediated antinociception by Î´ agonists: characterization with antagonists. European Journal of Pharmacology, 1989, 169, 43-52.	3.5	84
51	Development of a Rationally Designed, Low Abuse Potential, Biogenic Amine Releaser That Suppresses Cocaine Self-Administration. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 1361-1369.	2.5	83
52	Chronic administration of morphine and naltrexone up-regulate Î¼-opioid binding sites labeled by [3H][D-Ala2, MePhe4, Gly-ol5]enkephalin: further evidence for two Î¼-binding sites. European Journal of Pharmacology, 1989, 160, 71-82.	3.5	82
53	3,4â€methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse, 2004, 53, 240-248.	1.2	82
54	Antinociceptive and Hypothermic Effects of Salvinorin A Are Abolished in a Novel Strain of Î²-Opioid Receptor-1 Knockout Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 641-648.	2.5	80

#	Article	IF	Citations
55	Synthesis, Opioid Receptor Binding, and Biological Activities of Naltrexone-Derived Pyrido- and Pyrimidomorphinans. Journal of Medicinal Chemistry, 1999, 42, 3527-3538.	6.4	79
56	Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn-superoxide dismutase transgenic mice. Synapse, 1995, 21, 169-176.	1.2	78
57	Cocaine and GBR12909 produce equivalent motoric responses at different occupancy of the dopamine transporter. Pharmacology Biochemistry and Behavior, 1992, 43, 1135-1142.	2.9	77
58	Probes for Narcotic Receptor Mediated Phenomena. 23.1Synthesis, Opioid Receptor Binding, and Bioassay of the Highly Selective Î´ Agonist (+)-4-[(Î±R)-Î±-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80) and Related Novel Nonpeptide Î´ Opioid Receptor Ligands. Journal of Medicinal Chemistry, 1997, 40, 695-704.	6.4	77
59	Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochemical Pharmacology, 2008, 75, 2-16.	4.4	77
60	Lack of evidence for context-dependent cocaine-induced sensitization in humans: Preliminary studies. Pharmacology Biochemistry and Behavior, 1994, 49, 583-588.	2.9	75
61	Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. , 2000, 35, 222-227.		75
62	Sustained Decrease in Cocaine-Maintained Responding in Rhesus Monkeys with 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]- 4-(3-hydroxy-3-phenylpropyl)piperazinyl Decanoate, a Long-Acting Ester Derivative of GBR 12909. Journal of Medicinal Chemistry, 1996, 39, 4689-4691.	6.4	74
63	Identification of (3R)-7-Hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 432 Td (3,4-d Novel Potent and Selective Opioid Îº Receptor Antagonist. Journal of Medicinal Chemistry, 2003, 46, 3127-3137.	6.4	74
64	Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine. Psychopharmacology, 1996, 127, 10-18.	3.1	73
65	Identification of a GBR12935 homolog, LR1111, which is over 4,000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters. Synapse, 1993, 14, 34-39.	1.2	72
66	Alterations in the stereochemistry of the .kappa.-selective opioid agonist U50,488 result in high-affinity .sigma. ligands. Journal of Medicinal Chemistry, 1989, 32, 1996-2002.	6.4	71
67	Development of Novel, Potent, and Selective Dopamine Reuptake Inhibitors through Alteration of the Piperazine Ring of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909). Journal of Medicinal Chemistry, 1996, 39, 4704-4716.	6.4	70
68	(+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 1191-1199.	2.5	70
69	Effects of Dose and Route of Administration on Pharmacokinetics of (Â±)-3,4-Methylenedioxymethamphetamine in the Rat. Drug Metabolism and Disposition, 2009, 37, 2163-2170.	3.3	68
70	Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. European Journal of Pharmacology, 2002, 447, 51-57.	3.5	67
71	Salvinorin A: Allosteric Interactions at the Î¼-Opioid Receptor. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 801-810.	2.5	67
72	Effects of â€œLegal Xâ€•Piperazine Analogs on Dopamine and Serotonin Release in Rat Brain. Annals of the New York Academy of Sciences, 2004, 1025, 189-197.	3.8	66

#	Article	IF	Citations
73	Treatment with antisense oligodeoxynucleotide to the opioid Î´ receptor selectively inhibits Î´2-agonist antinociception. NeuroReport, 1994, 5, 1049-1052.	1.2	64
74	Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. Psychopharmacology, 2014, 231, 4135-4144.	3.1	64
75	Heteroaromatic Analogs of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as High-Affinity Dopamine Reuptake Inhibitors. Journal of Medicinal Chemistry, 1997, 40, 705-716.	6.4	63
76	Development of Long-Acting Dopamine Transporter Ligands as Potential Cocaine-Abuse Therapeutic Agents:â€‰ Chiral Hydroxyl-Containing Derivatives of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine. Journal of Medicinal Chemistry, 2002, 45, 1321-1329.	6.4	62
77	Herkinorin Analogues with Differential Î²-Arrestin-2 Interactions. Journal of Medicinal Chemistry, 2008, 51, 2421-2431.	6.4	62
78	Identification of an Opioid Îº Receptor Subtype-Selective N-Substituent for (+)-(3R,4R)-Dimethyl-4-(3-hydroxyphenyl)piperidine. Journal of Medicinal Chemistry, 1998, 41, 5188-5197.	6.4	61
79	Appetite Suppressants, Cardiac Valve Disease and Combination Pharmacotherapy. American Journal of Therapeutics, 2009, 16, 354-364.	0.9	60
80	Autoradiographic evidence for two classes of mu opioid binding sites in rat brain using [125I]FK33824. Peptides, 1987, 8, 1015-1021.	2.4	59
81	Identification of Opioid Ligands Possessing Mixed Î¼ Agonist/Î´ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydropmorphone. Journal of Medicinal Chemistry, 2004, 47, 1400-1412.	6.4	58
82	Preparation of rat brain membranes greatly enriched with either type-I-delta or type-II-delta opiate binding sites using site directed alkylating agents: Evidence for a two-site allosteric model. Neuropeptides, 1984, 4, 201-215.	2.2	57
83	Salvinicins A and B, New Neoclerodane Diterpenes fromSalviadivinorum. Organic Letters, 2005, 7, 3017-3020.	4.6	57
84	A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) Î¼-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse, 2007, 61, 166-175.	1.2	57
85	Dual dopamine/serotonin releasers: Potential treatment agents for stimulant addiction.. Experimental and Clinical Psychopharmacology, 2008, 16, 458-474.	1.8	57
86	High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse, 2003, 50, 233-239.	1.2	56
87	Synthesis and Pharmacological Evaluation of 3-(3,4-Dichlorophenyl)-1-indanamine Derivatives as Nonselective Ligands for Biogenic Amine Transporters. Journal of Medicinal Chemistry, 2004, 47, 2624-2634.	6.4	56
88	(Â±)-3,4-Methylenedioxymethamphetamine Administration to Rats Does Not Decrease Levels of the Serotonin Transporter Protein or Alter Its Distribution between Endosomes and the Plasma Membrane. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 1002-1012.	2.5	56
89	Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 604-610.	2.5	56
90	Allosteric modulation by leucine-enkephalin of [3H]naloxone binding in rat brain. European Journal of Pharmacology, 1981, 72, 365-368.	3.5	55

#	Article	IF	Citations
91	Upregulation of the opioid receptor complex by the chronic administration of morphine: A biochemical marker related to the development of tolerance and dependence. Peptides, 1991, 12, 151-160.	2.4	55
92	Dual dopamine/serotonin releasers as potential medications for stimulante and alcohol addictions. AAPS Journal, 2007, 9, E1-E10.	4.4	55
93	Biosynthesis of dopamine and serotonin in the rat brain after repeated cocaine injections: A microdissection mapping study. Synapse, 1993, 14, 40-50.	1.2	54
94	14-Alkoxy- and 14-Acyloxypyridomorphinans: Î¼ Agonist/Î´ Antagonist Opioid Analgesics with Diminished Tolerance and Dependence Side Effects. Journal of Medicinal Chemistry, 2012, 55, 8350-8363.	6.4	54
95	Tight binding dopamine reuptake inhibitors as cocaine antagonists. FEBS Letters, 1989, 257, 341-344.	2.8	53
96	Therapeutic Potential of Monoamine Transporter Substrates. Current Topics in Medicinal Chemistry, 2006, 6, 1845-1859.	2.1	53
97	Oxygenated Analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as Potential Extended-Action Cocaine-Abuse Therapeutic Agents. Journal of Medicinal Chemistry, 1999, 42, 5029-5042.	6.4	52
98	Synthetic Studies of Neoclerodane Diterpenes fromSalviadivinorum:Â Semisynthesis of Salvinicins A and B and Other Chemical Transformations of Salvinorin Aâ€. Journal of Natural Products, 2006, 69, 107-112.	3.0	52
99	Synthesis of Salvinorin A Analogues as Opioid Receptor Probes. Journal of Natural Products, 2006, 69, 914-918.	3.0	52
100	Studies of the biogenic amine transporters. II. A brief study on the use of [3H]DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists. Life Sciences, 1993, 53, PL267-PL272.	4.3	51
101	Phentermine/fenfluramine decreases cocaine self-administration in rhesus monkeys. NeuroReport, 1997, 8, 1347-1351.	1.2	51
102	Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans. , 1999, 32, 44-50.		50
103	GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [11C]raclopride continuous infusion PET scans. Synapse, 1999, 33, 268-273.	1.2	50
104	Pharmacological activities of optically pure enantiomers of the Îº opioid agonist, U50,488, and its cis diastereomer: evidence for three Îº receptor subtypes. European Journal of Pharmacology, 1989, 167, 345-353.	3.5	48
105	Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences. Peptides, 1992, 13, 977-987.	2.4	47
106	Phentermine and Fenfluramine: Preclinical Studies in Animal Models of Cocaine Addiction. Annals of the New York Academy of Sciences, 1998, 844, 59-74.	3.8	47
107	Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboonPapio anubis. Synapse, 2005, 56, 94-99.	1.2	47
108	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: Selective modification of the furan ring. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3170-3174.	2.2	47

#	Article	IF	Citations
109	Evidence for alterations in presynaptic serotonergic function during withdrawal from chronic cocaine in rats. European Journal of Pharmacology, 1995, 282, 87-93.	3.5	46
110	Region-specific up-regulation of opioid receptor binding in enkephalin knockout mice. Molecular Brain Research, 1999, 68, 193-197.	2.3	46
111	Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum:â€‰ Preparation and Opioid Receptor Activity of Salvinicin Analogues. Journal of Medicinal Chemistry, 2007, 50, 3596-3603.	6.4	46
112	Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. European Journal of Pharmacology, 2013, 699, 180-187.	3.5	46
113	Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian-derived FaRPs F-8-Famide (NPFF) and A-18-Famide, for opioid Î¼, Î´, , , or receptors. Peptides, 1994, 15, 401-404.	2.4	44
114	Functional Consequences of Central Serotonin Depletion Produced by Repeated Fenfluramine Administration in Rats. Journal of Neuroscience, 1998, 18, 9069-9077.	3.6	44
115	Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective ?/? antagonist in the [35S]-GTP-?-S functional binding assay. Synapse, 1999, 34, 83-94.	1.2	44
116	Design, Synthesis, and Monoamine Transporter Binding Site Affinities of Methoxy Derivatives of Indatraline. Journal of Medicinal Chemistry, 2000, 43, 4868-4876.	6.4	44
117	Hybrid Dopamine Uptake Blockerâ€“Serotonin Releaser Ligands: A New Twist on Transporter-Focused Therapeutics. ACS Medicinal Chemistry Letters, 2014, 5, 623-627.	2.8	43
118	Selective and enantiospecific acylation of .kappa.-opioid receptors by (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide. Demonstration of .kappa. receptor heterogeneity. Journal of Medicinal Chemistry, 1989, 32, 281-283.	6.4	42
119	Persistent Antagonism of Methamphetamine-Induced Dopamine Release in Rats Pretreated with GBR12909 Decanoate. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 1190-1197.	2.5	42
120	Effect of dopamine receptor antagonists on cocaine subjective effects: A naturalistic case study. Journal of Substance Abuse Treatment, 1997, 14, 249-258.	2.8	41
121	Behavioural and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats. Psychopharmacology, 1997, 131, 296-306.	3.1	41
122	Investigation of the N-Substituent Conformation Governing Potency and Î¼ Receptor Subtype-Selectivity in (+)-(3R,4R)-Dimethyl-4-(3-hydroxyphenyl)- piperidine Opioid Antagonists. Journal of Medicinal Chemistry, 1998, 41, 1980-1990.	6.4	41
123	Neural and Cardiac Toxicities Associated With 3,4-Methylenedioxymethamphetamine (MDMA). International Review of Neurobiology, 2009, 88, 257-296.	2.0	41
124	Synthesis, Opioid Receptor Binding, and Bioassay of Naltrindole Analogues Substituted in the Indolic Benzene Moiety. Journal of Medicinal Chemistry, 1998, 41, 2872-2881.	6.4	39
125	Î´ Opioid Affinity and Selectivity of 4-Hydroxy-3-methoxyindolomorphinan Analogues Related to Naltrindole. Journal of Medicinal Chemistry, 1999, 42, 1673-1679.	6.4	39
126	Dual dopamineâ€“5-HT releasers: potential treatment agents for cocaine addiction. Trends in Pharmacological Sciences, 2006, 27, 612-618.	8.7	39

#	Article	IF	Citations
127	Autoradiographic localization of a novel peptide binding site in rat brain using the substance P analog, eledoisin. Neuropeptides, 1984, 4, 343-349.	2.2	38
128	Chronic intracerebroventricular infusion of the antiopioid peptide, Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 (NPFF), downregulates mu opioid binding sites in rat brain. Peptides, 1993, 14, 1271-1277.	2.4	38
129	Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. American Journal of Cardiology, 2000, 85, 913-915.	1.6	38
130	Appetite Suppressants as Agonist Substitution Therapies for Stimulant Dependence. Annals of the New York Academy of Sciences, 2002, 965, 109-126.	3.8	38
131	Dopamine/serotonin releasers as medications for stimulant addictions. Progress in Brain Research, 2008, 172, 385-406.	1.4	38
132	Opioid peptide receptor studies, 11: Involvement of Tyr148, Trp318 and His319 of the rat ?-opioid receptor in binding of ?-selective ligands. , 1999, 32, 23-28.		37
133	Probes for Narcotic Receptor Mediated Phenomena. 34. Synthesis and Structureâ"Activity Relationships of a Potent Î¼-Agonist Î´-Antagonist and an Exceedingly Potent Antinociceptive in the Enantiomeric C9-Substituted 5-(3-Hydroxyphenyl)-N-phenylethylmorphan Series. Journal of Medicinal Chemistry, 2007, 50, 3765-3776.	6.4	37
134	Differential binding of opioid peptides and other drugs to two subtypes of opioid binding sites in mouse brain: Further evidence for Î´ receptor heterogeneity. Peptides, 1993, 14, 893-907.	2.4	36
135	Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A. MedChemComm, 2011, 2, 1217.	3.4	36
136	RTI-4614-4: An analog of (+)-cis-3-methylfentanyl with a 27,000-fold binding selectivity for mu versus delta opioid binding sites. Life Sciences, 1991, 48, PL111-PL116.	4.3	35
137	Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. Bioorganic and Medicinal Chemistry, 2000, 8, 2689-2692.	3.0	35
138	Studies of the Biogenic Amine Transporters. 14. Identification of Low-Efficacy â€œPartialâ€•Substrates for the Biogenic Amine Transporters. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 251-262.	2.5	35
139	Preparation of rat brain membranes highly enriched with opiate kappa binding sites using site-directed acylating agents: Optimization of assay conditions. Neuropeptides, 1985, 6, 503-516.	2.2	34
140	Enantiomers of Diastereomeric cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]-N-phenylpropanamides: Synthesis, X-ray Analysis, and Biological Activities. Journal of Medicinal Chemistry, 1995, 38, 1547-1557.	6.4	34
141	Synthesis and Transporter Binding Properties of Bridged Piperazine Analogues of 1-{2-[Bis(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine (GBR 12909). Journal of Medicinal Chemistry, 2000, 43, 4840-4849.	6.4	34
142	Evidence for a Role of Transporter-Mediated Currents in the Depletion of Brain Serotonin Induced by Serotonin Transporter Substrates. Neuropsychopharmacology, 2014, 39, 1355-1365.	5.4	34
143	Leucine enkephalin noncompetitively inhibits the binding of [3H]naloxone to the opiate mu-recognition site: Evidence for deltaâ†mu binding site interactions in vitro. Neuropeptides, 1985, 6, 351-363.	2.2	33
144	Letter to the editor. Journal of Substance Abuse Treatment, 1994, 11, 273-275.	2.8	33

#	Article	IF	Citations
145	N-Substituted 9Î²-Methyl-5-(3-hydroxyphenyl)morphans Are Opioid Receptor Pure Antagonists. Journal of Medicinal Chemistry, 1998, 41, 4143-4149.	6.4	33
146	Chapter 5 Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. The Alkaloids Chemistry and Biology, 2001, 56, 79-113.	2.0	33
147	Binding of radiolabeled opiates to slide-mounted sections of molded minced rat brain: A novel method for conducting radioreceptor assays. Neuropeptides, 1983, 3, 493-499.	2.2	32
148	Probes for narcotic receptor mediated phenomena. 15. (3S,4S)-(+)-trans-3-Methylfentanyl isothiocyanate, a potent site-directed acylating agent for the .delta.-opioid receptors in vitro. Journal of Medicinal Chemistry, 1989, 32, 1392-1398.	6.4	32
149	Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [35S]GTP-?-S functional binding assay. Synapse, 2001, 39, 64-69.	1.2	32
150	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: Exploration of the 1-position. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6111-6115.	2.2	32
151	Effect of Iboga Alkaloids on Âµ-Opioid Receptor-Coupled G Protein Activation. PLoS ONE, 2013, 8, e77262.	2.5	32
152	Chronic morphine upregulates a Î¼-opiate binding site labeled by [3H]cycloFOXY: a novel opiate antagonist suitable for positron emission tomography. European Journal of Pharmacology, 1987, 142, 73-81.	3.5	31
153	Effect ofN-Alkyl andN-Alkenyl Substituents in Noroxymorphindole, 17-Substituted-6,7-dehydro-4,5Î±-epoxy-3,14-dihydroxy-6,7:2â€˜,3â€˜-indolomorphinans, on Opioid Receptor Affinity, Selectivity, and Efficacy. Journal of Medicinal Chemistry, 2001, 44, 1471-1474.	6.4	31
154	Up-regulation of central muâ€“opioid receptors in a model of hepatic encephalopathy: A potential mechanism for increased sensitivity to morphine in liver failure. Life Sciences, 2002, 70, 1701-1708.	4.3	31
155	Probes for Narcotic Receptor Mediated Phenomena. Part 28: New Opioid Antagonists from Enantiomeric Analogues of 5-(3-Hydroxyphenyl)-N-phenylethylmorphan. Bioorganic and Medicinal Chemistry, 2002, 10, 3319-3329.	3.0	31
156	Semisynthetic neoclerodanes as kappa opioid receptor probes. Bioorganic and Medicinal Chemistry, 2012, 20, 3100-3110.	3.0	31
157	Effect of Î²-FNA on opiate receptor binding: Preliminary evidence for two types of Î¼ receptors. European Journal of Pharmacology, 1983, 95, 147-148.	3.5	30
158	Selective labeling of Îº2 opioid receptors in rat brain by [125I]IOXY: Interaction of opioid peptides and other drugs with multiple Îº2a binding sites. Peptides, 1993, 14, 1279-1293.	2.4	30
159	Downregulation of mu-opioid binding sites following chronic administration of neuropeptide FF (NPFF) and morphine. Peptides, 1996, 17, 389-397.	2.4	30
160	Synthetic studies of neoclerodane diterpenoids from Salvia splendens and evaluation of opioid receptor affinity. Tetrahedron, 2008, 64, 10041-10048.	1.9	30
161	Changes in feeding and locomotion induced by amphetamine analogs in rats. Drug and Alcohol Dependence, 2009, 100, 234-239.	3.2	30
162	Opioid Receptor Probes Derived from Cycloaddition of the Hallucinogen Natural Product Salvinorin A. Journal of Natural Products, 2011, 74, 718-726.	3.0	30

#	Article	IF	Citations
163	LY164929: a highly selective ligand for the lower affinity [3H]D-Ala2-D-Leu-5-enkephalin binding site. Neuropeptides, 1988, 11, 13-16.	2.2	29
164	An examination of the opiate receptor subtypes labeled by [3H]cyclofoxy: An opiate antagonist suitable for positron emission tomography. Biological Psychiatry, 1988, 23, 435-458.	1.3	29
165	[3H]1-[2-(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: Further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex. Synapse, 1991, 8, 289-300.	1.2	29
166	Synthesis and biological activity of 3-substituted 3-desoxynaltrindole derivatives. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 799-804.	2.2	29
167	Chronic Fenfluramine Administration Increases Plasma Serotonin (5-Hydroxytryptamine) to Nontoxic Levels. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 791-797.	2.5	29
168	Preliminary ligand binding data for subtypes of the delta opioid receptor in rat brain membranes. Life Sciences, 1991, 49, PL141-PL146.	4.3	28
169	Probes for narcotic receptor mediated phenomena. 18. Epimeric 6.alpha.- and 6.beta.-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5.alpha.-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluation, and radiochemistry of [125I]-6.beta.-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5.alpha.-epoxymorphinan. Journal of Medicinal Chemistry, 1992, 35, 2826-2835.	6.4	28
170	Pharmacological characterization of the cloned kappa opioid receptor as a kappa1b subtype. NeuroReport, 1994, 5, 2161-2164.	1.2	28
171	Synthesis and biological activity of 8Î²-substituted hydrocodone indole and hydromorphone indole derivatives. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 165-168.	2.2	28
172	Binding of the Amphetamine-like 1-Phenyl-piperazine to Monoamine Transporters. ACS Chemical Neuroscience, 2012, 3, 693-705.	3.5	28
173	Nonlinear Pharmacokinetics of (Â±)3,4-Methylenedioxymethamphetamine (MDMA) and Its Pharmacodynamic Consequences in the Rat. Drug Metabolism and Disposition, 2014, 42, 119-125.	3.3	28
174	Alpha-ethyltryptamines as dual dopamineâ€“serotonin releasers. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4754-4758.	2.2	28
175	Synthesis and absolute configuration of optically pure enantiomers of a Ï°-opioid receptor selective agonist. FEBS Letters, 1987, 223, 335-339.	2.8	27
176	A Marked Change of Receptor Affinity of the 2-Methyl-5-(3-hydroxyphenyl)morphans upon Attachment of an (E)-8-Benzylidene Moiety: Synthesis and Evaluation of a New Class of .sigma. Receptor Ligands. Journal of Medicinal Chemistry, 1994, 37, 3163-3170.	6.4	27
177	Acute sensitivity vs. context-specific sensitization to cocaine as a function of genotype. Pharmacology Biochemistry and Behavior, 1996, 53, 623-628.	2.9	27
178	Probes for Narcotic Receptor-Mediated Phenomena. 25.1Synthesis and Evaluation ofN-Alkyl-Substituted (Î±-Piperazinylbenzyl)benzamides as Novel, Highly Selective Î´ Opioid Receptor Agonists. Journal of Medicinal Chemistry, 1997, 40, 2936-2947.	6.4	27
179	Importance of Phenolic Address Groups in Opioid Kappa Receptor Selective Antagonists. Journal of Medicinal Chemistry, 2004, 47, 1070-1073.	6.4	27
180	Phenylpiperidine opioid antagonists that promote weight loss in rats have high affinity for the (enkephalin-sensitive) binding site. Peptides, 1993, 14, 17-20.	2.4	26

#	Article	IF	Citations
181	Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: Preliminary evidence for different binding domains. Neurochemical Research, 1994, 19, 201-208.	3.3	26
182	Endocrine responses during acute nicotine withdrawal. Pharmacology Biochemistry and Behavior, 1996, 55, 433-437.	2.9	26
183	Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects. Drug Development Research, 2000, 51, 52-65.	2.9	26
184	Discovery of an Opioid Î¹ Receptor Selective Pure Antagonist from a Library of N-Substituted 4Î²-Methyl-5-(3-hydroxyphenyl)morphans. Journal of Medicinal Chemistry, 2002, 45, 3524-3530.	6.4	26
185	Studies of the Biogenic Amine Transporters 15. Identification of Novel Allosteric Dopamine Transporter Ligands with Nanomolar Potency. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 529-538.	2.5	26
186	Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation. Brain Research, 1996, 737, 215-220.	2.2	25
187	Studies of the biogenic amine transporters. VII. Characterization of a novel cocaine binding site identified with [125I]RTI-55 in membranes prepared from human, monkey and guinea pig caudate. , 1998, 28, 322-338.		25
188	Evaluation of the conditioned reinforcing effects of phentermine and fenfluramine in the rat: Concordance with clinical studies. , 1998, 30, 107-111.		25
189	Studies of the Biogenic Amine Transporters. 13. Identification of â€œAgonistâ€•and â€œAntagonistâ€• Allosteric Modulators of Amphetamine-Induced Dopamine Release. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 718-728.	2.5	25
190	Treatment of Obesity With â€œCombinationâ€•Pharmacotherapy. American Journal of Therapeutics, 2010, 17, 596-603.	0.9	25
191	Effects of MDMA and related analogs on plasma 5-HT: Relevance to 5-HT transporters in blood and brain. European Journal of Pharmacology, 2012, 674, 337-344.	3.5	25
192	[3H]cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: Allosteric modulation by paroxetine. Neurochemical Research, 1992, 17, 1275-1283.	3.3	24
193	Identification and characterization of a novel allosteric modulator (SoRI-6238) of the serotonin transporter. Synapse, 2004, 53, 176-183.	1.2	24
194	Studies of the Biogenic Amine Transporters. 12. Identification of Novel Partial Inhibitors of Amphetamine-Induced Dopamine Release. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 286-295.	2.5	24
195	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors. Organic and Biomolecular Chemistry, 2009, 7, 3748.	2.8	24
196	Identification of a novel â€œalmost neutralâ€•Î¼â€•opioid receptor antagonist in CHO cells expressing the cloned human Î¼â€•opioid receptor. Synapse, 2010, 64, 280-288.	1.2	24
197	Interaction of leucine enkephalin with (3H)naloxone binding in rat brain: Evidence for an opioid receptor complex. Neurochemical Research, 1983, 8, 913-931.	3.3	23
198	Ligand selectivity of cloned human and rat opioid mu receptors. Synapse, 1995, 21, 60-64.	1.2	23

#	Article	IF	Citations
199	Probes for Narcotic Receptor Mediated Phenomena. 26.1-3Synthesis and Biological Evaluation of Diarylmethylpiperazines and Diarylmethylpiperidines as Novel, Nonpeptidic Î´ Opioid Receptor Ligands. Journal of Medicinal Chemistry, 1999, 42, 5455-5463.	6.4	23
200	Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 17. Highly Î´ Opioid Receptor Selective 14-Alkoxy-Substituted Indolo- and Benzofuromorphinans. Journal of Medicinal Chemistry, 2002, 45, 5378-5383.	6.4	23
201	Decreased striatal opiate Î´-receptors in the rat model of persistent dyskinesia induced by iminodipropionitrile. Neuroscience Letters, 1986, 72, 84-86.	2.1	22
202	Interaction of enantiomeric pairs of opiates with phencyclidine binding sites in rat brain: Identification of (+) pentazocine as a ligand potentially suitable for imaging sigma binding sites using positron emission tomography. Neuropeptides, 1988, 12, 1-5.	2.2	22
203	Interaction of ?-funaltrexamine with [3H]cycloFOXY binding in rat brain: Further evidence that ?-FNA alkylates the opioid receptor complex. Synapse, 1991, 8, 86-99.	1.2	22
204	Synthesis and Biological Evaluation of Tropane-like 1-{2-[Bis(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine (GBR 12909) Analogues. Journal of Medicinal Chemistry, 2001, 44, 3937-3945.	6.4	22
205	Serotonin (5-HT) precursor loading with 5-hydroxy-l-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat. Drug and Alcohol Dependence, 2010, 114, 147-52.	3.2	22
206	Probing the opioid receptor complex with (+)-trans-superfit. I. Evidence that [D-Pen2,D-Pen5]enkephalin interacts with high affinity at the Î´cx binding site. Peptides, 1991, 12, 359-364.	2.4	21
207	Effects of acute and chronic cocaine on the activity of tuberoinfundibular dopamine neurons in the rat. Brain Research, 1993, 608, 175-179.	2.2	21
208	Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor. Synapse, 2004, 52, 209-217.	1.2	21
209	Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a Âµ-agonist Î´-antagonist and Î´-inverse agonists. Organic and Biomolecular Chemistry, 2007, 5, 1177-1190.	2.8	21
210	Opioid peptide receptor studies. 1. Identification of a novel Î´-opioid receptor binding site in rat brain membranes. Peptides, 1995, 16, 191-198.	2.4	20
211	Regulation of Î¼ binding sites after chronic administration of antibodies directed against specific anti-opiate peptides. Peptides, 1998, 19, 1703-1709.	2.4	20
212	Probes for Narcotic Receptor-Mediated Phenomena. 27.1Synthesis and Pharmacological Evaluation of Selective Î´-Opioid Receptor Agonists from 4-[(Î±R)-Î±-(2S,5R)-4-Substituted-2,5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamides and Their Enantiomers. Journal of Medicinal Chemistry, 2000, 43, 3193-3196.	6.4	20
213	Serotonin (5â€HT) Transporter Ligands Affect Plasma 5â€HT in Rats. Annals of the New York Academy of Sciences, 2008, 1139, 268-284.	3.8	20
214	Physiological regulation of neurohypophyseal Îº-opiate receptors. Brain Research, 1988, 443, 398-402.	2.2	19
215	Synthesis of an affinity ligand (â€˜UPHITâ€™) for in vivo acylation of the Îº-opioid receptor. FEBS Letters, 1989, 249, 178-182.	2.8	19
216	Repeated cocaine administration reduces 5-HT1A-mediated prolactin secretion in rats. Neuroscience Letters, 1995, 193, 9-12.	2.1	19

#	Article	IF	Citations
217	Probes for Narcotic Receptor Mediated Phenomena. 37. Synthesis and Opioid Binding Affinity of the Final Pair of Oxide-Bridged Phenylmorphans, the Ortho- and Para-b-Isomers and Their N-Phenethyl Analogues, and the Synthesis of the N-Phenethyl Analogues of the Ortho- and Para-d-Isomers. Journal of Medicinal Chemistry, 2008, 51, 7866-7881.	6.4	19
218	Analysis of binding surfaces: A methodology appropriate for the investigation of complex receptor mechanisms and multiple neurotransmitter receptors. Neuropeptides, 1983, 4, 41-44.	2.2	18
219	Probes for narcotic receptor mediated phenomena. 17. Synthesis and evaluation of a series of trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (U50,488) related isothiocyanate derivatives as opioid receptor affinity ligands. Journal of Medicinal Chemistry, 1990, 33, 1171-1176.	6.4	18
220	Interaction of opioid peptides and other drugs with multiple Î´ncx binding sites in rat brain: Further evidence for heterogeneity. Peptides, 1992, 13, 1207-1213.	2.4	18
221	Withdrawal from chronic cocaine enhances behavioral sensitivity to the 5-HT2/1C agonist DOI. Biological Psychiatry, 1993, 34, 576-577.	1.3	18
222	Methamphetamine Dependence: Medication Development Efforts Based on the Dual Deficit Model of Stimulant Addiction. Annals of the New York Academy of Sciences, 2000, 914, 71-81.	3.8	18
223	Serotonin Transporters, Serotonin Release, and the Mechanism of Fenfluramine Neurotoxicity. Annals of the New York Academy of Sciences, 2000, 914, 172-186.	3.8	18
224	Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens. Molecular Brain Research, 2001, 87, 184-189.	2.3	18
225	Synthesis, opioid receptor binding, and functional activity of 5â€²-substituted 17-cyclopropylmethylpyrido[2â€²,3â€²:6,7]morphinans. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 529-532.	2.2	18
226	Discovery of the First N-Substituted 4Î²-Methyl-5-(3-hydroxyphenyl)morphan To Possess Highly Potent and Selective Opioid Î´ Receptor Antagonist Activity. Journal of Medicinal Chemistry, 2004, 47, 281-284.	6.4	18
227	Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors. Brain Research Bulletin, 2008, 77, 49-54.	3.0	18
228	Phentermine cardiovascular safety. American Journal of Emergency Medicine, 2009, 27, 1010-1013.	1.6	18
229	Stimulant sensitization in humans. Biological Psychiatry, 1997, 42, 230.	1.3	17
230	Piperidine Analogues of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 4371-4374.	6.4	17
231	Synthesis and dopamine transporter affinity of chiral 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as potential cocaine abuse therapeutic agents. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 553-556.	2.2	17
232	Structureâ€"Activity Relationship Studies of Highly Selective Inhibitors of the Dopamine Transporter:â€‰ N-Benzylpiperidine Analogues of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine. Journal of Medicinal Chemistry, 2003, 46, 1465-1469.	6.4	17
233	Studies of the Biogenic Amine Transporters. XI. Identification of a 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909) Analog That Allosterically Modulates the Serotonin Transporter. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 906-915.	2.5	17
234	Design and Synthesis of Promiscuous High-Affinity Monoamine Transporter Ligands:Â Unraveling Transporter Selectivity. Journal of Medicinal Chemistry, 2006, 49, 1766-1772.	6.4	17

#	Article	IF	Citations
235	Methamphetamine and Idiopathic Pulmonary Arterial Hypertension. Chest, 2007, 132, 1412-1413.	0.8	17
236	Multidimensional analysis of ligand binding data: Application to opioid receptors. Neuropeptides, 1983, 3, 367-377.	2.2	16
237	Effect of ?-FNA on Opiate ? Receptor Binding. Journal of Neurochemistry, 1984, 43, 1197-1199.	3.9	16
238	SoRI 9409, a non-peptide opioid Î¼ receptor agonist/Î´ receptor antagonist, fails to stimulate [35S]-GTP-Î³-S binding at cloned opioid receptors. Brain Research Bulletin, 2001, 55, 507-511.	3.0	16
239	Factors Influencing Agonist Potency and Selectivity for the Opioid Î´ Receptor Are Revealed in Structureâ^'Activity Relationship Studies of the 4-[(N-Substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides. Journal of Medicinal Chemistry, 2001, 44, 972-987.	6.4	16
240	Preclinical Evaluation of GBR12909 Decanoate as a Longâ€Acting Medication for Methamphetamine Dependence. Annals of the New York Academy of Sciences, 2002, 965, 92-108.	3.8	16
241	DAT/SERT selectivity of flexible GBR 12909 analogs modeled using 3D-QSAR methods. Bioorganic and Medicinal Chemistry, 2007, 15, 1146-1159.	3.0	16
242	Evidence for a Î¼â€“Î´ opioid receptor complex in CHO cells co-expressing Î¼ and Î´ opioid peptide receptors. Peptides, 2008, 29, 1424-1431.	2.4	16
243	Probes for Narcotic Receptor Mediated Phenomena. 41. Unusual Inverse Î¼-Agonists and Potent Î¼-Opioid Antagonists by Modification of the N-Substituent in Enantiomeric 5-(3-Hydroxyphenyl)morphans. Journal of Medicinal Chemistry, 2011, 54, 957-969.	6.4	16
244	Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys.. Experimental and Clinical Psychopharmacology, 2014, 22, 274-284.	1.8	16
245	Probing the opioid receptor complex with (+)-trans-SUPERFIT. II. Evidence that Î¼ ligands are noncompetitive inhibitors of the Î´cx opioid peptide binding site. Peptides, 1992, 13, 1137-1143.	2.4	15
246	A study of the effect of the irreversible delta receptor antagonist [d-Ala2,Leu5,Cys6]Enkephalin on and opioid binding sites in vitro and in vivo. Peptides, 1992, 13, 691-694.	2.4	15
247	Phentermine pretreatment antagonizes the cocaine-induced rise in mesolimbic dopamine. NeuroReport, 1996, 8, 7-9.	1.2	15
248	(Â±)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3053-3056.	2.2	15
249	Endogenous CART peptide regulates mu opioid and serotonin 5-HT2A receptors. Peptides, 2003, 24, 413-417.	2.4	15
250	A critical structural determinant of opioid receptor interaction with phenolic 5-phenylmorphans. Bioorganic and Medicinal Chemistry, 2004, 12, 4543-4550.	3.0	15
251	Evidence for noncompetitive modulation of substrateâ€induced serotonin release. Synapse, 2010, 64, 862-869.	1.2	15
252	Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine discrimination or self-administration in rhesus monkeys. International Journal of Neuropsychopharmacology, 2013, 16, 1985-1998.	2.1	15

#	Article	IF	Citations
253	Opioid peptide receptor studies. 3. Interaction of opioid peptides and other drugs with four subtypes of the Î¹2 receptor in guinea pig brain. Peptides, 1995, 16, 1083-1095.	2.4	14
254	Probes for Narcotic Receptor-Mediated Phenomena. 21. Novel Derivatives of 3-(1,2,3,4,5,11-Hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol-6-yl)- phenols with Improved Î´ Opioid Receptor Selectivity. Journal of Medicinal Chemistry, 1996, 39, 2081-2086.	6.4	14
255	Optically pure (â^')-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzamide displays selective binding and full agonist activity for the Î´ opioid receptor. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3347-3350.	2.2	14
256	Studies of the biogenic amine transporters. VIII: Identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding. Synapse, 2002, 43, 268-274.	1.2	14
257	Chronic Morphine Up-Regulates GÎ±12 and Cytoskeletal Proteins in Chinese Hamster Ovary Cells Expressing the Cloned Î¼ Opioid Receptor. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 248-255.	2.5	14
258	Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3371-3375.	2.2	14
259	Structureâ€“activity relationships of substituted N-benzyl piperidines in the GBR series: Synthesis of 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(2-trifluoromethylbenzyl)piperidine, an allosteric modulator of the serotonin transporter. Bioorganic and Medicinal Chemistry, 2006, 14, 3967-3973.	3.0	14
260	Serotonergic responsiveness in human cocaine users. Drug and Alcohol Dependence, 2007, 86, 207-213.	3.2	14
261	Synthesis and pharmacological effects of the enantiomers of the N-phenethyl analogues of the ortho and para e- and f-oxide-bridged phenylmorphans. Organic and Biomolecular Chemistry, 2008, 6, 2868.	2.8	14
262	Probes for Narcotic Receptor-Mediated Phenomena. 20. Alteration of Opioid Receptor Subtype Selectivity of the 5-(3-Hydroxyphenyl)morphans by Application of the Message-Address Concept: Preparation of .delta.-Opioid Receptor Ligands. Journal of Medicinal Chemistry, 1995, 38, 1523-1537.	6.4	13
263	Delta opioid binding selectivity of 3-ether analogs of naltrindole. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3435-3438.	2.2	13
264	Altered Gene Expression in Pulmonary Tissue of Tryptophan Hydroxylase-1 Knockout Mice: Implications for Pulmonary Arterial Hypertension. PLoS ONE, 2011, 6, e17735.	2.5	13
265	Tritiated-6-beta-fluoro-6-desoxy-oxymorphone: A highly selective ligand for the opiate mu receptor whose binding is characterized by low nonspecific binding. Neuropeptides, 1984, 4, 311-317.	2.2	12
266	Increased cortical serotonin-2 (5-HT-2) receptors in the iminodipropionitrile (IDPN)-model of persistent dyskinesia in the rat. Neuropeptides, 1987, 10, 175-180.	2.2	12
267	Tritiated-6-beta-fluoro-6-desoxy-oxymorphone ã€^[3H] FOXYã€‰: a new ligand and photoaffinity probe for the MU opioid receptors. Neuropeptides, 1988, 11, 1-6.	2.2	12
268	Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat ? opioid receptor. Synapse, 1998, 28, 117-124.	1.2	12
269	Neurochemical neutralization of amphetamine-type stimulants in rat brain by the indatraline analog (â^')-HY038. Brain Research Bulletin, 2000, 53, 821-826.	3.0	12
270	Substituted Amphetamines That Produce Long-Term Serotonin Depletion in Rat Brain (â€œNeurotoxicityâ€) Do Not Decrease Serotonin Transporter Protein Expression. Annals of the New York Academy of Sciences, 2004, 1025, 151-161.	3.8	12

#	Article	IF	Citations
271	Probes for Narcotic Receptor Mediated Phenomena. 39.(1) Enantiomeric N-Substituted Benzofuro[2,3-c]pyridin-6-ols: Synthesis and Topological Relationship to Oxide-Bridged Phenylmorphans(2)â€. Journal of Medicinal Chemistry, 2009, 52, 7570-7579.	6.4	12
272	The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes. Psychopharmacology, 2019, 236, 915-924.	3.1	12
273	Evidence for Heterogeneity of Kappa-Opioid Binding Sites: A Review of Data Obtained Using Brain Membranes Depleted of Mu and Delta Binding Sites With Irreversible Agents. Analgesia (Elmsford, N Y), 1994, 1, 27-49.	0.5	12
274	Morphine noncompetitively inhibits [3H]leucine enkephalin binding to membranes lacking type-II delta binding sites: Evidence for a two-site allosteric model. Neuropeptides, 1984, 4, 257-260.	2.2	11
275	[3H]cyclofoxy, a ligand suitable for positron emission tomography, labels mu and kappa opioid receptors. Neuropeptides, 1987, 10, 235-239.	2.2	11
276	(E)-8-Benzylidene Derivatives of 2-Methyl-5-(3-hydroxyphenyl)morphans: Highly Selective Ligands for the .sigma.2 Receptor Subtype. Journal of Medicinal Chemistry, 1995, 38, 4776-4785.	6.4	11
277	Opioid peptide receptor studies. 4. Antisense oligodeoxynucleotide to the delta opioid receptor delineates opioid receptor subtypes. Regulatory Peptides, 1995, 59, 247-253.	1.9	11
278	Libraries of opiate and anti-opiate peptidomimetics containing 2,3-methanoleucine. Bioorganic and Medicinal Chemistry, 1997, 5, 1867-1871.	3.0	11
279	Comparative neurobiological effects of ibogaine and MK-801 in rats. Drug and Alcohol Dependence, 2000, 59, 143-151.	3.2	11
280	Derivatives of 17-(2-methylallyl)-substituted noroxymorphone: variation of the delta address and its effects on affinity and selectivity for the delta opioid receptor. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2883-2885.	2.2	11
281	Further exploration of 1-{2-[Bis-(4-fluorophenyl)methoxy]ethyl}piperazine (GBR 12909): role of N-aromatic, N-heteroaromatic, and 3-oxygenated N-phenylpropyl substituents on affinity for the dopamine and serotonin transporter. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1385-1389.	2.2	11
282	Design and Synthesis of 2- and 3-Substituted-3-phenylpropyl Analogs of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: Role of Amino, Fluoro, Hydroxyl, Methoxyl, Methyl, Methylene, and Oxo Substituents on Affinity for the Dopamine and Serotonin Transporters. Journal of Medicinal Chemistry, 2008, 51, 2795-2806.	6.4	11
283	Synthesis and Opioid Activity of Enantiomeric N-Substituted 2,3,4,4a,5,6,7,7a-Octahydro-1H-benzofuro[3,2-e]isoquinolines. Journal of Medicinal Chemistry, 2010, 53, 1392-1396.	6.4	11
284	Opioid Peptide Receptor Studies. 6. The 3-Methylfentanyl Congeners RTI-4614-4 and Its Enantiomers Differ in Efficacy, Potency, and Intrinsic Efficacy as Measured by Stimulation of [³⁵S]GTP-Î³-S Binding Using Cloned Î¼-Opioid Receptors. Analgesia (Elmsford, N Y) Tj ETQq0 0 0 rgBT /Overl	0.5	11
285	Interaction of naloxone with the opioid receptor complex in vitro. Neurochemical Research, 1982, 7, 1375-1384.	3.3	10
286	Evidence that the delta-selective alkylating agent, FIT, alters the mu-noncompetitive opiate delta binding site. Neuropeptides, 1985, 6, 227-237.	2.2	10
287	Unexpectedly high levels of opioid peptides in rat brain membranes. Peptides, 1987, 8, 645-649.	2.4	10
288	Discovery of novel peptidic dopamine transporter ligands by screening a positional scanning combinatorial hexapeptide library. , 1999, 33, 239-246.		10

#	Article	IF	Citations
289	Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: Further evidence of kappa receptor heterogeneity. Synapse, 1999, 34, 256-265.	1.2	10
290	The Age-Adjusted Mortality Rate From Primary Pulmonary Hypertension, in Age Range 20 to 54 Years, Did Not Increase During the Years of Peak â€œPhen/Fenâ€•Use. Chest, 2000, 118, 1516-1517.	0.8	10
291	4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]- N , N -diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1281-1284.	2.2	10
292	Endogenous corticotropin releasing factor regulates adrenergic and opioid receptors. Peptides, 2002, 23, 2177-2180.	2.4	10
293	Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor. Synapse, 2003, 47, 1-9.	1.2	10
294	Design, synthesis, and characterization of 6Î²-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2811-2814.	2.2	10
295	Apparent down-regulation of rat brain Î¼ and Îº-opioid binding sites labelled with [3H]cycloFOXY following chronic administration of the potent 5-hydroxytryptamine reuptake blocker, clomipramine. Journal of Pharmacy and Pharmacology, 2011, 41, 865-867.	2.4	10
296	Probes for narcotic receptor mediated phenomena. 43. Synthesis of the ortho-a and para-a, and improved synthesis and optical resolution of the ortho-b and para-b oxide-bridged phenylmorphans: Compounds with moderate to low opioid-receptor affinity. Bioorganic and Medicinal Chemistry, 2011, 19, 4330-4337.	3.0	10
297	Opioid Peptide Receptor Studies. 13. Characterization of Opioid Antagonists With the [³⁵S]GTP-Î³-S Binding Assay. Analgesia (Elmsford, N Y), 1999, 4, 27-32.	0.5	10
298	N-substituted octahydro-4a-(3-hydroxyphenyl)-10a-methyl-benzo[g]isoquinolines are opioid receptor pure antagonists. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 3149-3152.	2.2	9
299	Neurochemical and Neuroendocrine Effects of Ibogaine in Rats: Comparison to MK-801. Annals of the New York Academy of Sciences, 1998, 844, 252-264.	3.8	9
300	Regulation of the rat brain endothelin system by endogenous Î²-endorphin. Peptides, 2006, 27, 769-774.	2.4	9
301	Synthetic studies on neoclerodane diterpenes from Salvia splendens: oxidative modifications of ring A. Tetrahedron, 2009, 65, 1708-1715.	1.9	9
302	Probes for narcotic receptor mediated phenomena. Part 42: Synthesis and in vitro pharmacological characterization of the N-methyl and N-phenethyl analogues of the racemic ortho-c and para-c oxide-bridged phenylmorphans. Bioorganic and Medicinal Chemistry, 2011, 19, 3434-3443.	3.0	9
303	Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective Î¼-antagonist activity. European Journal of Medicinal Chemistry, 2012, 50, 44-54.	5.5	9
304	MPTP lesions of the nigrostriatal dopaminergic projection decrease [3H]1-[1-(2-thienyl)cyclohexyl]-piperidine binding to PCP site 2: Further evidence that PCP site 2 is associated with the biogenic amine reuptake complex. Neurochemical Research, 1992, 17, 261-264.	3.3	8
305	Effects of phentermine and cocaine on fenfluramine-induced depletion of serotonin in mouse brain. Drug and Alcohol Dependence, 1996, 41, 71-74.	3.2	8
306	Resolution of two [35S]GTP-Î³-S binding sites and their response to chronic morphine treatment: A binding surface analysis. Brain Research Bulletin, 2000, 51, 357-362.	3.0	8

#	Article	IF	Citations
307	Cocaine-like discriminative stimulus effects of â€œnorepinephrine-preferringâ€•monoamine releasers: time course and interaction studies in rhesus monkeys. Psychopharmacology, 2017, 234, 3455-3465.	3.1	8
308	The potent opioid agonist, (+)-cis-3-methylfentanyl binds pseudoirreversibly to the opioid receptor complex in vitro and in vivo: Evidence for a novel mechanism of action. Life Sciences, 1990, 47, 2231-2240.	4.3	7
309	In Vivo Correlates of Central Serotonin Function after High-Dose Fenfluramine Administration. Annals of the New York Academy of Sciences, 1998, 844, 138-152.	3.8	7
310	Opioid Peptide Receptor Studies. 8. One of the Mouse Brain ÎNCX Binding Sites is Similar to the Cloned Mouse Opioid Î´ Receptor: Further Evidence for Heterogeneity of Î´ Opioid Receptors. Peptides, 1998, 19, 343-350.	2.4	7
311	Is phentermine an inhibitor of monoamine oxidase? A critical appraisal. Synapse, 1999, 32, 141-145.	1.2	7
312	Chronic exposure to antibodies directed against anti-opiate peptides alter Î´-opioid receptor levels. Peptides, 1999, 20, 1419-1424.	2.4	7
313	Perinatal lead exposure alters locomotion induced by amphetamine analogs in rats. Life Sciences, 2011, 88, 586-589.	4.3	7
314	High-performance liquid chromatographic resolution of synthetic opiate and â€œanti-opiateâ€•peptides from human plasma. Biomedical Applications, 1995, 667, 49-56.	1.7	6
315	Combined phentermine/fenfluramine administration and central serotonin neurons. Synapse, 1998, 28, 339-342.	1.2	6
316	Opioid peptide receptor studies. 9. Identification of a novel non-Î¼- non-Î´-like opioid peptide binding site in rat brain. Peptides, 1998, 19, 1079-1090.	2.4	6
317	Does phentermine inhibit monoamine oxidase?. Lancet, The, 1999, 353, 1362.	13.7	6
318	Studies of the biogenic amine transporters. 10. Characterization of a novel cocaine binding site in brain membranes prepared from dopamine transporter knockout mice. Synapse, 2002, 44, 94-105.	1.2	6
319	Novel ligands for the opioid receptors: synthesis and structureâ€“activity relationships among 5â€²-aryl and 5â€²-heteroaryl 17-cyclopropylmethyl-4,5Î±-epoxypyrido[2â€²,3â€²:6,7]morphinans. Bioorganic and Medicinal Chemistry, 2003, 11, 4143-4154.	3.0	6
320	In Vitro and In Vivo Assessment of Mu Opioid Receptor Constitutive Activity. Methods in Enzymology, 2010, 484, 413-443.	1.0	6
321	Probes for narcotic receptor mediated phenomena. 46. N-substituted-2,3,4,9,10,10a-hexahydro-1H-1,4a-(epiminoethano)phenanthren-6- and 8-ols â€“ Carbocyclic relatives of f-oxide-bridged phenylmorphans. European Journal of Medicinal Chemistry, 2012, 58, 557-567.	5.5	6
322	ALTERATIONS IN THE BINDING OF [3H]LEUCINE-ENKEPHALIN TO STRIATAL MEMBRANES BY ENDOGENOUS FACTORS. Journal of Neurochemistry, 1979, 33, 191-200.	3.9	5
323	RTI-4793-14, a new ligand with high affinity and selectivity for the (+)-MK801-insensitive [3H]1-[1-(2) Tj ETQq1 1 0.784314 rgBT /Ove	1.2	5
324	Diaryldimethylpiperazine ligands with Î¼- and Î´-opioid receptor affinity: Synthesis of (+)-4-[(Î±R)-Î±-(4-allyl-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide Bioorganic and Medicinal Chemistry, 2003, 11, 4761-4768.	3.0	5

#	Article	IF	Citations
325	Probes for narcotic receptor mediated phenomena. 40. N-Substituted cis-4a-ethyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-8-ols. Bioorganic and Medicinal Chemistry, 2010, 18, 91-99.	3.0	5
326	RE: Pulmonary Hypertension Associated with Use of Phentermine?. Yonsei Medical Journal, 2011, 52, 869.	2.2	5
327	Ionic conditions differentially affect 3H-DADL binding to type-I and type-II opiate delta receptors in vitro. Neuropeptides, 1984, 4, 261-268.	2.2	4
328	Chronic iminodipropionitrile (IDPN) causes no changes in the rat brain phencyclidine (PCP) receptor. Neuropeptides, 1986, 7, 259-263.	2.2	4
329	Opioid peptide receptor studies. 15. Relative efficacy of 4-[(N-allyl-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide and related compounds at the cloned human ?-opioid receptor. Synapse, 2001, 40, 269-274.	1.2	4
330	Anorexogen-Related Cardiac Valvulopathy. Annals of Internal Medicine, 2002, 136, 779.	3.9	4
331	Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2225-2228.	2.2	4
332	Targeted screening for biogenic amine transporters: Potential applications for natural products. Life Sciences, 2005, 78, 512-518.	4.3	4
333	The biogenic amine transporter activity of vinylogous amphetamine analogs. MedChemComm, 2016, 7, 1657-1663.	3.4	4
334	Pseudoallosteric modulation by (+)-MK801 of NMDA-coupled phencyclidine binding sites. Life Sciences, 1990, 47, PL77-PL82.	4.3	3
335	Dihydrocodeinone-hydrazone, dihydrocodeinone-oxime, naloxone-3-ome-oxime, and clocinnamox fail to irreversibly inhibit opioid kappa receptor binding. Neurochemical Research, 1994, 19, 1159-1163.	3.3	3
336	An electrophilic affinity ligand based on (+)-MK801 distinguishes PCP site 1 from PCP site 2. Neurochemical Research, 1994, 19, 385-389.	3.3	3
337	Effects of electroconvulsive shock on the retention of cocaine-induced conditioning. Pharmacology Biochemistry and Behavior, 1994, 49, 399-404.	2.9	3
338	The Effect of FMRFamide Analogs on [35S]GTP-Î³-S Stimulation in Squid Optic Lobes. Peptides, 1998, 19, 739-747.	2.4	3
339	TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) inhibits the consumption of â€œsnacksâ€• in mice. Pharmacology Biochemistry and Behavior, 2006, 84, 74-83.	2.9	3
340	An efficient synthesis of 3-OBn-6Î²,14-epoxy-bridged opiates from naltrexone and identification of a related dual MOR inverse agonist/KOR agonist. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6801-6805.	2.2	3
341	Probes for narcotic receptor mediated phenomena. 48. C7- and C8-substituted 5-phenylmorphan opioids from diastereoselective alkylation. European Journal of Medicinal Chemistry, 2013, 67, 335-343.	5.5	3
342	Dual Dopamine/Serotonin Releasers as Potential Medications for Stimulant and Alcohol Addictions. , 2008, , 311.		3

#	Article	IF	Citations
343	Probes for narcotic receptor mediated phenomena. 47.1 Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols. Bioorganic and Medicinal Chemistry, 2013, 21, 3298-3309.	3.0	2
344	Interrogating the Activity of Ligands at Monoamine Transporters in Rat Brain Synaptosomes. Neuromethods, 2016, , 41-52.	0.3	2
345	Novel Opioid Antagonists with Mixed/Dual Selectivity. , 2009, , 137-151.		2
346	Opioid Peptide Receptor Studies 2. [³H]SNC-121, a Novel, Selective, and High-Affinity Ligand for Opioid Delta Receptors. Analgesia (Elmsford, N Y), 1995, 1, 185-193.	0.5	2
347	Multiple opioid receptors: An examination of the dissociation of [3H]leucine enkephalin from rat brain membranes. Neurochemical Research, 1983, 8, 179-184.	3.3	1
348	Rat brain PCP receptors: Alterations in binding parameters following chronic administration of opiate agonists and antagonists. Neuropeptides, 1987, 10, 201-205.	2.2	1
349	Intracerebroventricular administration of superFIT and its enantiomer to rats: Evidence for in vivo acylation of [3H]DADL binding sites. Neuropeptides, 1987, 9, 207-210.	2.2	1
350	6?-[125Iodo]-3, 14-dihydroxy-17-methyl-4, 5?-epoxymorphinan ([125I]IOXY-AGO): A potent and selective radioligand for opioid ? receptors. Synapse, 1995, 19, 105-111.	1.2	1
351	Probes for narcotic receptor mediated phenomena 22. (1) synthesis and characterization of optically pure [3H](+)-4-[(Î±R)-Î±-((2S, 5R)-4-propyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N, N-diethylbenzamide, [3H]SNC 121, a novel high affinity and select. Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 38, 847-850.	1.0	1
352	Modulation of Guanosine-5â€²-<B><I>O</I></B>-(3-[³⁵S]thio)triphosphate ([³⁵S]GTP-Î³-S) Binding by Opioid Agonists and Antagonists. Reviews in Analgesia, 2003, 7, 83-96.	0.9	1
353	Probes for narcotic receptor mediated phenomena 49. N-substituted rac-cis-4a-arylalkyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols. European Journal of Medicinal Chemistry, 2015, 92, 531-539.	5.5	1
354	Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects. Drug Development Research, 2000, 51, 52-65.	2.9	1
355	Chronic ICV infusion of morphine and NPFF down-regulate mu opioid receptors in rat brain: A quantitative autoradiographic study. Regulatory Peptides, 1994, 54, 107-108.	1.9	0
356	Reply:. American Journal of Cardiology, 2000, 86, 810-811.	1.6	0
357	Synthesis and Dopamine Transporter Affinity of Chiral 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as Potential Cocaine Abuse Therapeutic Agents.. ChemInform, 2003, 34, no.	0.0	0
358	A study of bile acids as opioid receptor ligands in rat brain membranes. Neuroscience Letters, 2004, 358, 68-70.	2.1	0
359	Phentermine cardiovascular safety. International Journal of Cardiology, 2010, 144, 241-242.	1.7	0
360	Phentermine cardiovascular safety II: Response to Yosefy Int J Cardiol. 2009 Epub Mar 19. International Journal of Cardiology, 2010, 145, 391-392.	1.7	0

#	Article	IF	Citations
361	The Case of Posterior Reversible Encephalopathy With Intracranial Hemorrhage was Likely due to Uncontrolled Hypertension, and was Unrelated and Coincidental to Long-term Phentermine Use. Neurologist, 2015, 19, 118-119.	0.7	0